ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4. A total of 19 filers reported holding ENDOLOGIX INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $49,220,000 | +6.7% | 51,117,000 | 0.0% | 1.90% | -0.1% |
| Q4 2016 | $46,140,000 | +17.6% | 51,117,000 | +24.9% | 1.90% | +4.1% |
| Q3 2016 | $39,231,000 | +3.8% | 40,941,000 | 0.0% | 1.82% | +22.9% |
| Q2 2016 | $37,787,000 | +26.5% | 40,941,000 | 0.0% | 1.48% | +16.7% |
| Q1 2016 | $29,871,000 | -13.7% | 40,941,000 | 0.0% | 1.27% | -9.3% |
| Q4 2015 | $34,602,000 | -6.2% | 40,941,000 | 0.0% | 1.40% | -1.8% |
| Q3 2015 | $36,877,000 | -7.3% | 40,941,000 | 0.0% | 1.43% | +7.7% |
| Q2 2015 | $39,784,000 | +13.0% | 40,941,000 | +17.2% | 1.32% | +16.2% |
| Q1 2015 | $35,203,000 | +1.9% | 34,925,000 | 0.0% | 1.14% | -8.2% |
| Q4 2014 | $34,562,000 | +82.6% | 34,925,000 | +64.4% | 1.24% | +80.0% |
| Q3 2014 | $18,932,000 | +51.2% | 21,240,000 | +70.6% | 0.69% | +37.2% |
| Q2 2014 | $12,520,000 | +4.9% | 12,450,000 | 0.0% | 0.50% | +3.3% |
| Q1 2014 | $11,930,000 | – | 12,450,000 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 51,117,000 | $46,140,000 | 1.90% |
| PFM Health Sciences, LP | 6,445,000 | $5,809,000 | 0.16% |
| Partner Investment Management, L.P. | 84,000 | $76,000 | 0.10% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 5,562,000 | $5,013,000 | 0.09% |
| OAKTREE CAPITAL MANAGEMENT LP | 6,000,000 | $5,423,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,095,000 | $1,004,000 | 0.04% |
| ACUTA CAPITAL PARTNERS, LLC | 96,000 | $86,000 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,500,000 | $1,352,000,000 | 0.03% |
| AMUNDI ASSET MANAGEMENT US, INC. | 7,305,000 | $6,557,000 | 0.02% |
| Citadel Advisors | 6,230,000 | $5,624,000 | 0.01% |